Alzheimer Disease - Drug therapy
Research News and Information

Saturday, November 21, 2009

Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway.

29 Nov 2009 Calcium/calmodulin-dependent protein kinase IV (CaMKIV) plays a key role in the regulation of calcium-dependent gene expression. The expression of CaMKIV and the activation of CREB regulated genes are involved in memory and neuronal survival. We ... Read more...

Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders.

29 Sep 2009 Protein accumulation leads to CNS effects in Alzheimer's disease, frontotemporal dementia, and other age-related disorders. Common mechanisms may contribute to the progressive pathology in the different protein accumulation disorders, and ... Read more...

Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD.

29 Sep 2009 The mechanisms responsible for oxidative damage, pathological brain iron deposition and mitochondrial insufficiency in Alzheimer disease (AD) remain enigmatic. Heme oxygenase-1 (HO-1) is a 32 kDa stress protein that catabolizes heme to biliverdin, ... Read more...

Latest indexed articles for 'Alzheimer Disease - Drug therapy'

These are the very latest articles for this heading:

• Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. 29 Nov 2009
• Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Nov 2009
• Alzheimer's biomarker initiative hits its stride. 14 Oct 2009
• Adverse events in patients receiving cholinesterase inhibitors due to dissimilar follow-up periods. 10 Oct 2009
• Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders. 29 Sep 2009
• Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. 29 Sep 2009
• A neurotrophic rationale for the therapy of neurodegenerative disorders. 29 Sep 2009
• Modulation and detection of tau aggregation with small-molecule ligands. 29 Sep 2009
• A multi-targeted approach for a complex multifaceted disease. 29 Sep 2009
• Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. 29 Sep 2009
• Turbocharging the brain. 29 Sep 2009
• If shrimps had lips, they could whistle ... 29 Sep 2009
• Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. 29 Sep 2009
• The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. 29 Sep 2009
• [Final report is now available. IQWiG doubts the effectiveness of memantine] 22 Sep 2009
• Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. 8 Sep 2009
• Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. 6 Sep 2009
• Klotho is a substrate for alpha-, beta- and gamma-secretase. 4 Sep 2009
• Synthesis of sominone and its derivatives based on an RCM strategy: discovery of a novel anti-Alzheimer's disease medicine candidate "denosomin". Sep 2009
• Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. 31 Aug 2009

See a longer list of these articles.

Technical information about 'Alzheimer Disease'

Definition: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Descriptor UI: D000544

Alternative terms: Alzheimer Disease; Disease, Alzheimer; Dementia, Senile; Dementias, Senile; Senile Dementia; Senile Dementias; Dementia, Primary Senile Degenerative; Senile Dementia, Alzheimer Type; Alzheimer Type Senile Dementia; Primary Senile Degenerative Dementia; Alzheimer's Disease; Disease, Alzheimer's; Dementia, Alzheimer Type; Alzheimer Type Dementia; Dementia, Presenile; Dementias, Presenile; Presenile Dementia; Presenile Dementias; Alzheimer Disease, Late Onset; Late Onset Alzheimer Disease; Alzheimer's Disease, Focal Onset; Focal Onset Alzheimer's Disease; Acute Confusional Senile Dementia; Senile Dementia, Acute Confusional; Alzheimer Disease, Early Onset; Early Onset Alzheimer Disease; Presenile Alzheimer Dementia; Alzheimer Dementia, Presenile; Dementia, Presenile Alzheimer;

Related Mesh Headings: Amyloid beta-Protein; Amyloid beta-Protein Precursor; Cerebral Amyloid Angiopathy; tau Proteins; Neurofilament Proteins; Aphasia, Primary Progressive; Kluver-Bucy Syndrome;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C10.228.140.380.100; C10.574.945.249; F03.087.400.100;

History Note: 1998(1963); for DEMENTIA, PRESENILE and DEMENTIA, PRIMARY DEGENERATIVE SENILE use DEMENTIA 1981-1999; for DEMENTIA SENILE use DEMENTIA 1966-1999